TY - JOUR
T1 - Remote skin self-examination training of melanoma survivors and their skin check partners
T2 - A randomized trial and comparison with in-person training
AU - Robinson, June K.
AU - Reavy, Racheal
AU - Mallett, Kimberly A.
AU - Turrisi, Rob
N1 - Funding Information:
Supported by R01 CA154908 to June K. Robinson, MD, from the National Cancer Institute. The sponsor was not involved in a) design and conduct of the study, b) collection, management, analysis, and interpretation of data, c) preparation, review, or approval of the manuscript, or d) decision to submit the manuscript for publication.
Publisher Copyright:
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Background: Compared with other cancers, melanoma has the longest delays measured as the median time to patient presentation for care from symptom onset. Time to presentation for care is a key determinant of outcomes, including disease stage, prognosis, and treatment. Methods: Melanoma survivors with localized disease and their skin check partners enrolled in two sequential randomized control trials of skin self-examination (SSE) training. In Phase 1, the pair read a workbook in the office and had quarterly total body skin examinations with a study dermatologist. In Phase 2, materials were mailed to pairs, whose surveillance was with a community physician. SSE knowledge, performance (frequency and extent), and identification of concerning moles were compared between phases. Results: Among 341 patients, 197 received the workbook and the others were controls. Knowledge in performing SSE was higher for the workbook relative to controls in both phases. The SSE frequency ranged from 2.38 to 5.97 times in 9 months. Patients randomized to the workbook in both phases performed significantly more SSE than controls at 9 months (P <.05). In both phases, trained survivors performed significantly more SSEs on the scalp than controls at 9 and 18 months (P <.05). Phase 1 survivors performed significantly more SSEs on the abdomen, buttocks, and soles of the feet than controls, but this did not occur in Phase 2. Finally, in both phases, survivors trained with the workbook resulted in greater detection of suspicious lesions and melanomas. Conclusions: These findings justify the benefits of remote SSE training for patients as an adjunct to provider-administered screening.
AB - Background: Compared with other cancers, melanoma has the longest delays measured as the median time to patient presentation for care from symptom onset. Time to presentation for care is a key determinant of outcomes, including disease stage, prognosis, and treatment. Methods: Melanoma survivors with localized disease and their skin check partners enrolled in two sequential randomized control trials of skin self-examination (SSE) training. In Phase 1, the pair read a workbook in the office and had quarterly total body skin examinations with a study dermatologist. In Phase 2, materials were mailed to pairs, whose surveillance was with a community physician. SSE knowledge, performance (frequency and extent), and identification of concerning moles were compared between phases. Results: Among 341 patients, 197 received the workbook and the others were controls. Knowledge in performing SSE was higher for the workbook relative to controls in both phases. The SSE frequency ranged from 2.38 to 5.97 times in 9 months. Patients randomized to the workbook in both phases performed significantly more SSE than controls at 9 months (P <.05). In both phases, trained survivors performed significantly more SSEs on the scalp than controls at 9 and 18 months (P <.05). Phase 1 survivors performed significantly more SSEs on the abdomen, buttocks, and soles of the feet than controls, but this did not occur in Phase 2. Finally, in both phases, survivors trained with the workbook resulted in greater detection of suspicious lesions and melanomas. Conclusions: These findings justify the benefits of remote SSE training for patients as an adjunct to provider-administered screening.
UR - http://www.scopus.com/inward/record.url?scp=85089026186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089026186&partnerID=8YFLogxK
U2 - 10.1002/cam4.3299
DO - 10.1002/cam4.3299
M3 - Article
C2 - 32761987
AN - SCOPUS:85089026186
SN - 2045-7634
VL - 9
SP - 7301
EP - 7309
JO - Cancer medicine
JF - Cancer medicine
IS - 19
ER -